Iron-saturated bovine lactoferrin: a promising chemopreventive agent for hepatocellular carcinoma
Hury Viridiana Hernández‐Galdámez, Samia Fattel‐Fazenda, Teresita del N.J. Flores-Téllez, Mario Alejandro Aguilar‐Chaparro, Jonathan Mendoza-García, Lidia C. Díaz-Fernández, Eunice Romo-Medina, Yesennia Sánchez-Pérez, Jaime Arellanes‐Robledo, Mireya de la Garza, Saúl Villa‐Treviño, Carolina Piña‐Vázquez
Abstract
model, such as necrosis, ROS production, and the surge of facultative liver stem cells, and eventually, holo-bLf reduced the number of preneoplastic lesions. For an established HCC model, holo-bLf treatment significantly reduced HepG2 tumor burden in xenotransplanted mice. Finally, holo-bLf in combination with sorafenib, the advanced HCC first-line treatment, synergistically decreased HepG2 viability by arresting cells in the G0/G1 phase of the cell cycle. Our findings provide the first evidence suggesting that holo-bLf has the potential to prevent HCC or to be used in combination with treatments for established HCC.